Abstract
Background Use of masks and respirators for prevention of respiratory infectious disease transmission is not new, but has proven controversial, and even politically polarizing during the SARS-CoV-2 pandemic. In the Canadian province of Ontario, mask mandates were introduced by the 34 regional health authorities in an irregular fashion from June to September 2020, creating a quasi-experiment that can be used to evaluate impact of community mask mandates. Ontario SARS-CoV-2 case counts were strongly biased by testing focussed on long-term care facilities and healthcare workers. We developed a simple regression-based test-adjustment method that allowed us to adjust cases for undertesting by age and gender. We used this test- adjusted time series to evaluate mask mandate effectiveness.
Methods We evaluated the effect of masking using count-based regression models that allowed adjustment for age, sex, public health region and time trends with either reported (unadjusted) cases, or testing-adjusted case counts, as dependent variables. Mask mandates were assumed to take effect in the week after their introduction. Model based estimates of effectiveness were used to estimate the fraction of SARS- CoV-2 cases, severe outcomes, and costs, averted by mask mandates.
Results Models that used unadjusted cases as dependent variable identified protective effects of masking (effectiveness 15-42%), though effectiveness was variably statistically significant, depending on model choice. Mask effectiveness in models predicting test-adjusted case counts was substantially higher, ranging from 49% (44- 53%) to 73% (48-86%) depending on model choice. Effectiveness was greater in women than men (P = 0.016), and in urban health units as compared to rural units (P < 0.001). The prevented fraction associated with mask mandates was 46% (41-51%), averting approximately 290,000 clinical cases, averting 3008 deaths and loss of 29,038 QALY. Costs averted represented $CDN 610 million in economic wealth.
Conclusions Lack of adjustment for SARS-CoV-2 undertesting in younger individuals and males generated biased estimates of infection risk and obscures the impact of public health preventive measures. After adjustment for under-testing, the effectiveness of mask mandates emerges as substantial, and robust regardless of model choice. Mask mandates saved substantial numbers of lives, and prevented economic costs, during the SARS-CoV-2 pandemic in Ontario, Canada.
Competing Interest Statement
DF has served on advisory boards for respiratory vaccines manufactured by Pfizer, Seqirus, Sanofi, Merck and AstraZeneca. ART is an employee of the Public Health Agency of Canada. Other authors, no competing interests.
Funding Statement
The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Aggregate data files needed for replication of results are available at https://figshare.com/articles/dataset/Data_for_Fisman_et_al_Test-Adjusted_Incidence_of_COVID-19_in_Ontario/14036528. The study was approved by the Research Ethics Board of the University of Toronto (protocol number 00044787).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Aggregate data files needed for replication of results are available at https://figshare.com/articles/dataset/Data_for_Fisman_et_al_Test-Adjusted_Incidence_of_COVID-19_in_Ontario/14036528. The study was approved by the Research Ethics Board of the University of Toronto (protocol number 00044787).